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ABSTRACT 
Hydrogen sulfide (H2S) is a novel signaling molecule most recently found to be of fundamental 
importance in cellular function as a regulator of apoptosis, inflammation, and perfusion. Mechanisms of 
endogenous H2S signaling are poorly understood, however, signal transmission is thought to occur via 
persulfidation at reactive cysteine residues on proteins. Although much has been discovered about how H2S 
is synthesized in the body, less is known about how it is metabolized. Recent studies have discovered a 
multitude of different targets for H2S therapy, including those related to protein modification, intracellular 
signaling, and ion channel depolarization. The most difficult part of studying hydrogen sulfide has been 
finding a way to accurately and reproducibly measure it. The purpose of this review is to: 1) elaborate on the 
biosynthesis and catabolism of H2S in the human body, 2) review current knowledge of the mechanisms of 
action of this gas in relation to ischemic injury, 3) define strategies for physiological measurement of H2S in 
biological systems, and 4) review potential novel therapies that use H2S for treatment.  
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BACKGROUND 
Hydrogen sulfide (H2S) is a colorless, flammable, malodorous gas that portends the smell of rotten 
eggs. It has previously been appreciated for its toxic effects, but more recently, has been found to facilitate a 
number of beneficial biological activities.  It has been dubbed the “third gasotransmitter” alongside carbon 
monoxide (CO) and nitric oxide (NO). However, most literature suggests that it does not signal in its 
gaseous state but rather as a persulfide or polysulfide.  Endogenously created, these signaling molecules 
travel both intracellularly and intercellularly. Pathways of these gasotransmitters may interact with and 
impact each other and have been implicated in regulation of many physiological processes(1). The effects of 
H2S have been studied on various physiological platforms, most notably in the regulation of cellular 
metabolism, inflammation, the immunological response, ischemia and cardiovascular biology(1, 2).  
With the recent discovery of H2S as a physiological signaling molecule, its’ role in end organ 
protection following ischemia has come into question.  H2S could prove to be a novel drug for utilization in a 
variety of ischemic disorders, including those of the intestine, heart, and brain(3-5). Through this review we 
aim to: 1) elaborate on the biosynthesis and catabolism of H2S in the human body, 2) review current 
knowledge of the mechanisms of action of this gas in relation to ischemic injury, 3) define strategies for 
physiological measurement of H2S in biological systems, and 4) review potential novel therapeutic agents 
that use H2S therapy for treatment.  
BIOSYNTHESIS OF H2S 
Enzymatic Synthesis 
Hydrogen sulfide is endogenously produced in mammalian tissues by both enzymatic and non-
enzymatic pathways (i.e., reduction of thiols and thiol containing molecules).  The enzymes involved in 
synthesis of H2S include: cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-
mercaptopyruvate sulfurtransferase (3-MPST) in collaboration with cysteine aminotransferase (CAT). These 
enzymes convert cysteine and homocysteine to H2S gas and specific byproducts such as serine, pyruvate, 
and cystathionine (Figure 1)(6).  They also play a significant role in transsulfuration and reverse 
transsulfuration pathways, the formation of persulfides, and protein persulfidation. 
The majority of H2S is produced by the two pyridoxal-5’phosphate (PLP) dependent enzymes, CBS 
and CSE in which homocysteine is metabolized to cysteine. CBS is a predominant enzyme in the central 
nervous system but can also be found in the liver, kidney, pancreas, lungs, endothelial cells and 
gastrointestinal tract(7-9).CSE is expressed in the liver, uterus, placenta, pancreatic islets, brain, 
gastrointestinal, cardiovascular, renal and pulmonary systems (7, 10, 11). Both of these enzymes are located 
in the cytosol but can traverse to the mitochondria during stress (12, 13). Specifically when exposed to 
hypoxic stress, an increase in intracellular levels of calcium triggers CSE translocation from the cytosol to 
the mitochondria to sustain mitochondrial ATP production (13). In the mitochondria, cysteine is available at 
triple the concentration of that in the cytosol. Cysteine is metabolized by CSE to produce H2S and 
mitochondrial ATP production is increased in the presence of H2S in hypoxic conditions(13).  
3-MPST, is a zinc-dependent enzyme located in both the mitochondria and cytosol, with majority
located in mitochondria (12). Regarding the 3-MPST pathway, CAT, a PLP-dependent enzyme, converts L-
cysteine and 2-ketoglutarate to 3-mercaptopyruvate (3-MP) and glutamate respectively. The reaction of 3-
MP with 3-MPST forms a polysulfide on the enzyme. Production of H2S from 3-MPST requires the 
endogenous reducing cofactors thioredoxin and dihydrolipoic acid. Through the reaction of 3-MP with 3-
MPST, 3-MP is converted to H2S, pyruvate and NH3 (Figure 1). Additionally, 3-MPST has been found to 
also convert D-cysteine to H2S in the presence of D-amino acid oxidase (14). CAT and MPST are found in 
multiple organ systems most notably the cardiovascular, renal, liver, lung, thymus, testis, brain and thoracic 
aorta (8). MPST and CAT are both detected in vascular endothelium and vascular smooth muscle cells 
(VMSCs).  
Intracellular Sulfur Stores 
H2S may also be formed from bound sulfane sulfur (intracellular sulfur stores) and has demonstrated 
potential importance in certain cells and certain cellular conditions(15, 16) (Table 1). H2S is carried on 
proteins attached to another sulfur as a persulfide or trisulfide. Carrier proteins of protein-bound sulfane 
sulfur in tissues include rhodanese, CBS, CSE, MPST, albumin, cytochrome, and ferredoxin(15). The sulfur 
is labile and has the distinctive ability to reversibly attach to other sulfur atoms and create elemental sulfur, 
persulfides, polysulfides, thiosulfate, and polythionates(16).  
Rhodanese, CSE and MPST are the most commonly described carrier proteins and are widely 
distributed within animal tissues. These carrier proteins allow transport of sulfur to various acceptors and are 
of physiologic importance. If labeled cysteine (precursor of H2S), is injected into an animal, labeled bound 
sulfane sulfur is rapidly detected(17). Bound sulfur can be stored or transported in a less labile, nongaseous 
state to be released later through this reversible binding process. When H2S oxidizes cysteine thiols to forms 
stable persulfides which under reducing conditions can release stored H2S (18). Liver and kidney tissues 
have both demonstrated high amounts of bound sulfur(18). 
Sulfide Signaling – Is it H2S or other sulfide mediators? 
Evidence in literature suggests that H2S signaling may be mediated endogenously by polysulfides 
(RSnR, RSnH, H2Sn; R=radical group, n>2) and/or persulfides (n=2)(19). Persulfides and/or polysulfides 
bind to reactive cysteine residues on proteins causing persulfidation (aka S-sulfhydration; changing –SH 
group of cysteine to an –SSH or persulfide) and thereby changing the functional properties of specific 
proteins. Over fifteen sulfhydrated proteins have been identified (20). While the significance of polysulfides 
in H2S signaling has only recently been recognized, physiologic regulation by these sulfhydrated proteins 
has been observed in the brain with activation of transient receptor potential ankyrin 1 (TRPA1) channels, 
tensin homolog activity, and persulfidation of Kelch-like ECH-associated protein 1 allowing translocation of 
nuclear factor erythroid 2-related factor 2 to the nucleus (21). Polysulfides are potential signaling molecules 
modulating the activity of enzymes, channels and receptors through protein persulfidation. 
In addition to polysulfides and persulfides, thiosulfate (S2O32-), an intermediate in oxidative H2S 
metabolism has also been touted as a contributing member of H2S signaling under hypoxic conditions as an 
oxygen sensor. Olson et al. has demonstrated that while H2S is usually oxidized to form thiosulfate, H2S 
metabolism can alternatively cause the regeneration of H2S via thiol reduction in hypoxic conditions (22).  
Lastly, sulfite (SO23-) has also been reported to play a role with increased production via oxidation of H2S by 
LPS-activated neutrophils as a result of oxidative stress and may play a key role in the setting of 
inflammation or hypoxia(23).  All of this emerging evidence of other sulfide mediators demonstrates that 
further work is required to delineate this fine balance and the intricacy of H2S mediated pathways.  
Toxicity of Hydrogen Sulfide 
It is thought that the dose response relationship between toxic and physiologic effects of H2S is very 
steep. H2S has been found to have dual regulation in the mitochondria exhibiting both inhibitory and 
stimulatory effects. At lower concentrations H2S acts as a mitochondrial substrate, similar to NADH or 
FADH2, donating electrons at sulfide quinone oxidoreductase (SQR) and stimulating the production of ATP 
and thus increasing metabolism(24). However, at high concentrations, H2S has been found to reversibly and 
competitively bind to cytochrome c oxidase; inhibiting the binding of oxygen. With this inhibition, the 
electron transport chain is no longer able to move electrons and ATP production comes to a halt. By 
inhibiting mitochondrial respiration, a positive feedback loop results with increasing H2S accumulation and a 
decreased oxidation rate that accelerates H2S accumulation, leading to further suppression of the 
mitochondrial function.  
H2S toxicity is measured in parts per million (ppm) and it has been found that 300ppm causes 
pulmonary edema with pulmonary vasoconstriction and systemic vasodilation(25), while higher 
concentrations nearing 1000ppm cause immediate death. Higher levels of H2S result in free radical 
generation, glutathione deletion, intracellular iron release, and pro-apoptotic action through the death 
receptor and mitochondrial pathways (8).  
The steady state of H2S concentrations within tissues is very low because it is rapidly metabolized in 
mitochondria. Overall, cytoprotective effects have been found in nanomolar (nM) and micromolar (µM) 
concentrations of H2S while higher millimolar (mM) H2S exposure tends to be cytotoxic (26).  The effective 
concentration (EC50) values for H2S have been studied in a few tissues and appear to be in the µM range.  
For example, in intestinal muscle, the H2S-donor, sodium hydrosulfide (NaHS), was found to induce 
concentration-dependent muscle relaxation and EC50 values reported in the literature have ranged from 31-
514 µM (27, 28). Vascular tissues have been slightly more sensitive to NaHS with EC50 values ranging 
between 104 – 136 µM (27).  
Lastly, the concentration-dependent benefit vs. harm of H2S becomes even more fascinating in the 
sub-toxic concentrations of H2S. With intermediate levels of H2S, there is competitive inhibition of 
cytochrome c oxidase with oxygen consumption declining due to this inhibition. A study by Blackstone et al. 
utilized gaseous H2S to induce ‘suspended animation’ in mice in which mice were placed in a hibernation-
like state causing hypometabolic effects(29). In this study, they demonstrated a concentration-dependent 
reduction in core body temperature, total-body CO2 production and O2 consumption secondary to inhaled 
H2S therapy. Similarly, this hypometabolism was also observed in a porcine model of aortic occlusion with 
intravenous administration of Na2S. There was a markedly reduced utilization of catecholamines, decreased 
CO2 production and O2 uptake (30). Blackstone et al. found this sulfide-mediated reduction in metabolism 
was also found to be protective in the setting of lethal hypoxia(31). H2S-induced ‘suspended animation’ mice 
could survive hypoxia (5% O2) for up to 6 hours while all animals in the control group died within 17 
minutes (31). This H2S-induced hypometabolism may be highly protective in different clinical scenarios of 
hypoxia and ischemia.  
CATABOLISM OF H2S 
Hydrogen sulfide catabolism occurs through 1) expiration and excretion, 2) oxidation, 3) 
methylation, and 4) scavenging (12). Urinary excretion represents a major metabolic and excretory pathway 
of H2S with over 50% of orally administered (35S)-barium sulfide in rats being excreted as sulfate or ethereal 
sulfate within 24 hours(32). H2S has also been found to be excreted in feces and flatus as free sulfide.  
However this method only accounts for 8-10% of doses recovered in studies examining excretion (32, 33). 
Secretion of H2S via exhalation has also been demonstrated after intravenous sodium sulfide (Na2S) 
administration(33). Sodium sulfide, when administered, dissociates to sodium (Na+) and the hydrosulfide 
anion (HS-), which then forms H2S gas that may be expired during exhalation.  
In the mitochondria, H2S degradation occurs through rapid oxidation to thiosulfate and is further 
converted to sulfite and sulfate(19). Sulfur oxidation begins with catabolism of H2S by SQR, a mitochondrial 
membrane flavoprotein, which oxidizes H2S to sulfane sulfur forming a persulfide (SQRS-S)(19). 
Ubiquinone accepts the electrons in this reaction and transfers them to complex III and IV of the electron 
transport chain moving electrons to a terminal electron acceptor (O2) via a series of redox reaction resulting 
in a transmembrane proton gradient used to make ATP via ATP synthase. Further steps in H2S catabolism 
occur via persulfide dioxygenase, rhodanese, and sulfite oxidase, which creates thiosulfate (SSO32-) and 
sulfate (SO42-) as final end products. Oxidation of H2S to thiosulfate can be affected by heme compounds, 
ferritin, and metalloprotein complexes(34). 
While oxidation occurs in the mitochondria, H2S is catabolized via methylation in the cytosol. H2S 
can also undergo cytosolic methylation by thiol-S-methyltransferase to yield methanethiol and 
dimethylsulfide(35). Lastly, H2S may be scavenged by methemoglobin to yield sulfhemoglobin or by 
metallo- or disulfide containing molecules.  
MECHANISMS OF ACTION 
H2S has a number of beneficial properties that can be useful in the treatment of end organ ischemia. 
It targets proteins within endothelium, epithelium, and smooth muscle. Known effects of H2S include 1) 
vascular relaxation, 2) vascular angiogenesis, 3) modulation of cell death and apoptosis, 4) reduction of 
inflammatory processes, and 5) cytoprotection (Figure 2).  
Vascular Relaxation 
Hydrogen sulfide has been found to be a key modulator of both vascular relaxation and vascular 
angiogenesis, both of which contribute to increased blood flow following intestinal ischemic injury. In 
VMSCs, H2S has been shown to modulate vasorelaxation via opening of potassium-dependent ATP (KATP) 
channels in a number of vessels including the aorta, mesenteric arteries, hepatic artery and portal vein (36-
38). Persulfidation of Cys34 on the Kir6.1 subunit of the KATP channel in smooth muscle cells induces 
vasodilation by preventing association of ATP with the channel(39). Phospathidyl-inositol-4, 5-bisphosphate 
is consequently able to bind to the channel leading to channel opening, K+ influx, and smooth muscle 
relaxation. H2S was also observed to upregulate KATP channel expression, thereby enhancing vasorelaxation 
in spontaneously hypertensive rats (40). Additionally, angiotensin-converting enzyme, a zinc-containing 
enzyme that normally causes vasoconstriction, may be inhibited in a dose-dependent manner by H2S 
interaction with zinc.  This effect may add to the vasodilatory influence of KATP channels.   
The opening of KATP channels also hyperpolarizes the cell membrane and inactivates voltage-
dependent L-type Ca2+ channels. This leads to cell relaxation and blood vessel dilation by decreasing 
intracellular Ca2+. Large conductance Ca2+-activated potassium (BKCa) channels, also present in VMSCs, 
have demonstrated increased vasodilatory effects in the presence of NaHS (H2S donor; sulfide salt) in rat 
mesenteric rat arteries(41). This mechanism was inhibited by use of a ryanodine blocker, a BKCa blocker, 
and by endothelial disruption.  
Additionally, both CBS and CSE are vital and interdependent modulators of blood pressure and 
vasorelaxation. Rats given both aminooxyacetic acid (a CBS inhibitor) andDL-propargyl glycine (PAG; a 
CSE inhibitor) would develop hypertension. However, if only one of the inhibitors was administered, the 
other enzyme’s activity was upregulated to maintain endogenous H2S levels (42). It has also been found that 
mesenteric artery cholinergic relaxation was reduced by 75-80% in mice with homozygous CSE deletion and 
by 50% in heterozygotes (43). CSE has been found to be highly localized in the endothelial layer of blood 
vessels. Studies using CSE knockout mice have demonstrated pronounced hypertension and diminished 
endothelium-dependent vasorelaxation (43). Additionally, Cheng et al. observed that the presence or absence 
of the endothelium in the mesenteric artery bed played a significant role in the vasodilatory properties of H2S 
and that H2S-induced vasorelaxation of mesenteric artery beds is at least partially mediated by the 
endothelium via an endothelium derived hyperpolarizing factor related mechanism (37).  These studies 
demonstrate that the ability to endogenously produce H2S within the vascular endothelium plays a vital role 
in vascular relaxation.  
When specifically examining mesenteric artery beds (MAB), Cheng et al. found ~20% MAB 
relaxation with applications of < 1 µM H2S, and, with greater concentrations (>10 µM H2S) there was >90% 
relaxation(37). Additionally, when L-cysteine, a pre-curser to H2S production was added, this was also found 
to produce vasodilation while the addition of a CSE inhibitor caused attenuation of the vasodilatory effects 
(37). In a pig model, the benefits of H2S on mesenteric perfusion have been observed with a two fold 
increase in mesenteric perfusion following ischemic injury with application of NaHS (44). Thus, with 
application of an H2S donor following intestinal ischemic injury, a direct vasorelaxant effect on mesenteric 
arteriolar smooth muscle may be observed, enhancing end organ mesenteric perfusion and preferentially 
distributing blood flow to the damaged intestinal mucosa(44).  
Vascular Angiogenesis  
Hydrogen sulfide has been found to exhibit potent angiogenic properties. This concept was 
demonstrated with an observed dose-dependent increase in endothelial cell proliferation, enhanced capillary-
like structure formation, increased motility, and increased length and number of vascular formations (45, 
46).  H2S promotes angiogenesis via pathways involving vascular endothelial growth factor (VEGF), protein 
kinase B (AKT) and p38.  H2S activation of these pathways enhances endothelial migration (45). When p38 
and AKT inhibitors are used, H2S-induced migration was respectively decreased or blocked completely (45). 
In another study, NaHS was observed to mediate AKT phosphorylation.  However, there was no effect on 
p38.  This may have been due to lower experimental levels of NaHS administration (10 µM vs. 60 µM 
NaHS in previous study) (46). Both of these studies demonstrate the intricate biological pathways of H2S 
modulation of neovascularization. Additionally, if further demonstrates the critical dose response 
relationship seen with therapeutic H2S application.  
VEGF receptor 2 (VEGFR2), a mediator of most of the biological effects of VEGF, has also been 
found to be modified by H2S to facilitate its activation after ligand binding (47). H2S promotes increased 
binding VEGF to VEGFR2, thereby enhancing migration and growth of vascular endothelial cells. In CBS 
deficient endothelial cells, there was decreased H2S production and significant transcriptional down 
regulation of VEGFR2 and neuropilin 1. This down-regulation was mediated by specificity protein 1 which 
has been found to be regulated via persulfidation of Cys68 and Cys755. When H2S was administered, 
specificity protein 1 levels were restored, and there was an increase in both VEGFR2 and NRP-1 
expression(9).   
In addition to endothelial cells, H2S also regulates VSMC proliferation and apoptosis. This regulation 
is vital and key to vascular remodeling. If CSE is overexpressed to produce higher levels of endogenous H2S 
or if H2S is exogenously applied, there is inhibition of proliferation and induction of apoptosis in aortic 
VSMCs via MAPK pathway activation of ERK and caspase 3 (48). Additionally, in the development of 
balloon injury-induced neointimal hyperplasia there is decreased CSE expression and H2S production. 
However treatment with NaHS induces vasorelaxation and significantly inhibits neointima formation by 
decreasing VSMC proliferation(49). These findings demonstrate the importance of H2S in VSMC 
modulation.  
Various ischemia and reperfusion models have shown increased angiogenesis with the application of 
H2S. In hind limb ischemia, NaHS has been observed to increase regional blood flow to ischemic tissues 
after femoral artery ligation, to promote collateral vessel growth and to cause an increase in capillary 
density(50). In murine myocardial infarction models, mice that underwent ligation of the left anterior 
descending artery and administration of NaHS were found to have increased expression of angiogenic 
factors (VEGF, flk-1, flt-1), and decreased levels of anti-angiogenic factors (endostatin, angiostatin, 
parstatin)(51). Improved angiogenesis was also visualized by radiographic and Doppler blood flow 
measurements(51).  
The pro-angiogenic effects of H2S converge on the same downstream molecular target as NO. The 
angiogenesis and wound healing effects of H2S were completely absent in endothelial nitric oxide (eNOS) 
knock out mice. If H2S production was reduced through CSE inhibition, NO-stimulated angiogenesis was 
significantly decreased(52). NO and H2S are mutually dependent and converge at cyclic guanosine 5’-
monophosphate (cGMP). NO activates soluble guanylyl cyclase to generate cGMP whereas H2S inhibits 
phosphodiesterase type 5 inhibitor to slow down the degradation of cGMP(52). With an increase in cGMP 
there is increased activation of protein kinase G with its subsequent downstream effects.  
Cell Death and Apoptosis 
In addition to the direct stimulatory effects of H2S on vasodilation, cell growth, and angiogenesis, it 
also plays a role in modulating cell death and apoptosis. The endothelium covers the inner surface of the 
cardiovascular system and protects the vascular system from inflammatory damage, provides a permeability 
barrier to control blood volume and osmotic homeostasis. The endothelium is also where the earliest signs of 
vascular inflammation are detected with propagation of pro-inflammatory cytokines, upregulated expression 
of adhesion molecules, adherence of leukocytes to the vascular endothelium, and subsequent extravasation 
and migration to sites of injury. In previous studies, H2S has demonstrated the ability to inhibit vascular 
inflammation through multiple different pathways, including inhibition of p38 and nuclear factor k light-
chain enhancer of activated B cells (NF-kB), activation of KATP and BKCa channels as well as heme 
oxygenase 1 expression (53). H2S is also known to decrease reactive oxygen species levels in endothelial 
cells through scavenging reactive oxygen species. Many of the antioxidant enzymes including catalase, 
superoxide dismutase, glutathione peroxidase, and glutathione-S-transferase are upregulated in the presence 
of H2S. Reduced glutathione production is also increased with H2S accounting for additional cytoprotective 
effects seen in endothelial cells. 
GAPDH, a known regulator of a cell death cascade can be sulfhydrated by a polysulfide at Cys150 
causing a dramatic increase in its enzymatic activity(54). The anti-apoptotic transcription factor, NF- κB has 
also been observed to be sulfhydrated on Cys38 of the p65 subunit.  The addition of the sulfur moiety 
promotes NF- κB binding to co-activator ribosomal protein S3 to facilitate its further binding to promoters of 
anti-apoptotic genes (55).  
Cell death during ischemia and following reperfusion are fundamental to the pathology of ischemic 
injury. By decreasing cell death and apoptosis, H2S has the capacity to lessen tissue injury and accelerate 
recovery and repair following ischemia. Understanding how to manipulate this gasotransmitter to reduce cell 
death is paramount for treatment strategies. 
Inflammation and Sepsis 
 Literature regarding the role of H2S in inflammation and sepsis has been somewhat controversial and 
contradicting. While some research in the literature has noted H2S’ ability to decrease the production of 
inflammatory cytokines, others have demonstrated an up regulation of apoptosis and H2S formation 
following inflammation.  However, similar debates have arisen in the literature regarding two other 
inflammatory mediators; nitric oxide and prostaglandins. To some extent the differences in observations are 
dose-related, drug and model dependent, and related to setting. The contradictory findings largely reflect 
variations in dose-response relationships with low, physiologic concentrations being anti-inflammatory, 
while higher concentrations promote inflammation as also seen with NO and CO(56, 57).  
Studies implicating H2S as a pro-inflammatory mediator include that of Zhang et al., who used a 
mouse model of cecal ligation and puncture (CLP) induced sepsis (58).  Mice were treated with either PAG 
(50mg/kg; intraperitoneal), a CSE inhibitor, or NaHS (10 mg/kg; intraperitoneal) (58). With the induction of 
sepsis, CSE mRNA production in the liver was significantly upregulated. They also found a significant down 
regulation of inflammation after administration of PAG (IL-1β, IL-6, TNF-α, monocyte chemotactic protein-
1 and macrophage inflammatory protein 2). Additionally, PAG reduced myeloperoxidase (MPO) activity 
and histological changes in the lung and liver. However, in contrast, there was an upregulation of pro-
inflammatory markers with administration of NaHS. This H2S mediated systemic inflammation was thought 
to occur through a mechanism involving activation of ERK pathway and upregulation of NF-κB activity. 
Similarly, in a study by Li et al., mice underwent intraperitoneal E. coli LPS administration and 
demonstrated a dose-dependent increase in plasma H2S concentration and an increase in CSE gene 
expression in both kidney and liver tissues (59). This same pro-inflammatory effect was confirmed with 
administration of NaHS which similarly increased MPO activity and increased plasma TNF-α concentration. 
Similarly, when PAG was administered there was a decrease in MPO activity in the lung and liver (59). 
In contrast to the literature noting the pro-inflammatory effects of H2S, a more recent article of CLP 
sepsis demonstrated opposite effects, and noted attenuation of pro-inflammatory markers (IL-1β, IL-5, IL-6, 
TNF-α, HMGB1) following NaHS administration (60). In this particular study, survival and end-organ blood 
flow was increased when NaHS (3mg/kg) was administered via intraperitoneal injection 24 hours post-CLP 
(72). This dose was a lower concentration than the previous studies demonstrating pro-inflammatory effects 
(3mg/kg vs 10 mg/kg), thereby suggesting a bimodal dose response. In a study using a rats to model gastric 
I/R injury, administration of NaHS caused the pro-inflammatory cytokines, IL-1B and TNF-a, to be 
significantly decreased in a dose dependent manner(61). Additionally, the highest amount of area with 
mucosal lesions was seen in rats treated with PAG (61). 
In other studies examining inflammatory properties, H2S has been found to be an important 
endogenous regulator of leukocyte activation and trafficking during the inflammatory response, and 
similarly to above studies, pro- or anti-inflammatory effects vary dependent on dose. Zanardo et al. 
demonstrated that H2S donors (NaHS 1-150 µmol/kg) suppress leukocyte adherence to vascular endothelium 
and reduce leukocyte infiltration and edema formation (53). Additionally, when inhibited by CSE inhibitor, 
there was enhanced leukocyte adhesion, leukocyte infiltration and edema formation mediated via KATP 
channels(53). Conversely, in a study done by Zhang, et al. when PAG was given to block endogenous 
production of NaHS in a septic mouse, there was reduced leukocyte rolling and adhesion in mesenteric 
venules along with decreased ICAM-1, P-selectin and E-selectin production (62). Additionally, when 
exogenous NaHS (10 mg/kg) was administered to a septic mouse, there was increased leukocyte rolling and 
adhesion along with increased levels of ICAM-1, P-selectin and E-selectin (62).  This difference in pro-
inflammatory and anti-inflammatory effects is most notably dose-dependent.  
It is unclear from the current body of literature if H2S is a pro-inflammatory or anti-inflammatory 
mediator.  Although its effects are likely dose dependent, it is unclear at this point what the most optimal 
dose for therapy is.  Further studies are needed to quantify the dose response curve in various models of end 
organ ischemia to provide an appropriate dose that inhibits the inflammatory response. 
Cytoprotection 
The majority of research into the cytoprotective effects of H2S in ischemia-reperfusion injury has 
been done in both renal and cardiac injury models. In cardiac I/R injury, the administration of NaHS has 
been found to enhance the activity of CSE, reduce ischemic injury, and attenuate the injury to organelles 
(mitochondria, nucleus and myofilaments). This has been demonstrated by a reduction of lactate 
dehydrogenase activity, decreased mitochondrial malondialdehyde, and an increase in the activities of 
reactive oxygen species scavengers (superoxide dismutase and glutathione peroxidase) (63). Xiao et al. 
found that H2S decreased cell injury in cardiomyocytes following hypoxic injury by regulating autophagy 
pathways and mTOR activation (64). Additionally in a study by Sivarajah et al. the administration of NaHS 
following myocardial ischemic insult caused a significant decrease in both apoptosis and caspase 9 activity 
while increasing the production of anti-apoptotic protein Bcl-2 (65). The benefit of this NaHS therapy was 
abolished with the application of a mitochondrial KATP blocker suggesting mediation of anti-apoptotic effects 
through this pathway (65).  Multiple other studies have also confirmed the ability of H2S to provide 
protection to cardiomyocytes following ischemia and reperfusion injury(66, 67).  
H2S has also been shown to be protective in a number of renal ischemia and reperfusion models.  In 
an in vitro model of hypoxia/oxidative stress injury, glucose oxidase stimulation led to mitochondrial 
dysfunction and decreased intracellular ATP, and, at higher concentrations, necrosis and increased 
intracellular oxidant formation (68). However, when the mitochondrially-targeted H2S donor A39 was 
administered, there was a dose-dependent decrease in the observed injury. This was translated into an in vivo 
rat model of renal I/R injury and A39 was found to provide dose-dependent protection against all known 
signs of oxidative stress. Additionally, there was decreased neutrophil infiltration and BUN and creatinine 
levels were decreased, thus, attenuating the inflammatory and oxidative processes(68).  
Han et al. demonstrated similar findings with the use of NaHS following renal ischemia-reperfusion 
injury. In their study, NaHS was found to accelerate recovery of renal function and tubular morphology and 
to decrease the production of reactive oxygen species(69). Furthermore, when PAG was added they found 
delayed recovery following injury(69). More importantly, with their study, they also found a resultant 
decrease in CSE and CBS expression/activity following ischemia that did not return until 8 days after 
ischemia. This would suggest that during ischemia, the ability to produce adequate endogenous H2S is 
significantly reduced, and therefore, exogenous applications are required to restore homeostasis. Similarly, 
in a study by Stenzel et al., the ability to preserve renal function and high creatinine clearance following 
renal I/R was found to be correlated with the ability to maintain high expression of CSE(70). When 
examining the benefits of pre-treatment with an H2S donor prior to aortic occlusion in a porcine model, 
Simon et al. observed similar benefits with attenuated kidney dysfunction,  decreased inflammation, and 
decreased iNOS expression and NO release (71).  These findings support the notion that novel exogenous 
H2S therapy could change management and potential outcomes following ischemic injuries. 
Interactions and Interdependency between Gasotransmitters 
When looking at differences between gasotransmitter signaling, it is apparent that different vascular 
beds have different thresholds for gasotransmitter mediated vascular relaxation.  Therefore, NO and H2S 
induced vasorelaxation via endothelium-dependent mechanisms may vary by blood vessel type.  For 
example, H2S is 5 times more potent in rat mesenteric artery (EC50 ~ 25 µM) compared to rat aorta (EC50 
~125 µM)(72), and therefore has a greater role in mesenteric artery vasorelaxation, while the aorta displays 
more prominent NO-mediated relaxation(73). In the aorta, Coletta et al. reported that when aortic endothelial 
cells are exposed to H2S, intracellular cGMP, activated PKG and vasodilator-stimulated phosphoprotein all 
increase in an NO-dependent manner. When inhibitors of these cellular proteins are used, the angiogenic and 
vasodilatory properties of this pathway are not elicited demonstrating the unique requirement of NO in 
vascular H2S signaling within the aorta(52).  
Gasotransmitter signaling may also be dependent on one another.  H2S has been found to upregulate 
NO production through persulfidation of eNOS(74). Altaany et al. demonstrated at Cys443 was the primary 
persulfidation site in eNOS and once sulfhyrated by H2S, dimerization of eNOS occurred activating the 
protein for NO production. Additionally, wild-type mice and CSE knockout mice were also compared and 
eNOS dimerization was predominately found in wild-type mice whereas eNOS monomers were prevalent in 
the CSE-knockout mice (only eNOS dimers produce NO) further confirming gasotransmitter 
interdependency. In a cardiac study of rats with metabolic syndrome (obesity, high triglycerides, fasting 
blood sugar and blood pressure) established by a 16-week high fat diet, both H2S and NO yielded synergistic 
effects in myocardial tissue. In these animals, there was an increase in the expression of both CSE and eNOS 
mRNA. When CSE was inhibited, nitric oxide levels increased, as did the expression of eNOS and iNOS. 
With use of an H2S donor, eNOS and iNOS were significantly decreased. In the myocardium, NO and H2S 
appear to work synergistically to provide cardiac protection (75). Sodium nitroprusside, a source of NO, 
reacts directly with H2S yielding a redox sibling of nitric oxide known as nitroxyl (76). Nitroxyl activates 
sensory chemoreceptor TRPA1 by formation of amino-terminal disulfide bonds (77). This transformation 
allows for sustained calcium influx, the release of calcitonin gene-related peptide, and ultimately, local and 
systemic vasodilatation within the cardiovascular system (76). This reaction between NO and H2S also 
produces polysulfides that might also play a role in vasodilation, however this has yet to be studied.   
MEASURING H2S in PHYSIOLOGICAL SYSTEMS 
When at physiological pH of 7.4, dissolved H2S gas is a weak acid and in equilibrium H2S↔HS-
↔S2- (pKa1 = 6.9, pKa2 = >12) with one third as H2S and two thirds as HS- with very little S2- in extracellular 
fluids and plasma(78). Intracellularly, H2S exists as both the free form (with equal parts H2S and HS- at pH 
~6.9) and in a variety of bound forms including persulfides (thiosulfate, hydrosulfides), thiosulfonates, 
polysulfides, polythionates and iron-sulfur clusters.  
Many of the methods currently used to measure H2S were originally developed to measure and 
determine sulfide concentration in air and water samples and were subsequently applied to biological 
samples. Through experience we have learned that many of these methods provide inaccurate measurements 
of physiologically active H2S.  Therefore, finding a reliable, accurate, and reproducible method for in vivo 
and in vitro H2S measurement has continued to be exceedingly difficult. In addition to the multiple sources 
of H2S, there have also been multiple techniques and experimental conditions by which values in the 
literature have been obtained and reported(78). Due to its volatile nature and low steady state concentrations, 
obtaining reliable measures of H2S in biological samples continues to be a challenge. The methodologies that 
are most frequently used are discussed.    
Methylene Blue Assay 
The most common method of detecting H2S is a colorimetric assay using spectrophotometry in which 
H2S is trapped with a metal (usually zinc) followed by acidification and a reaction with a dye, N,N-dimethyl-
p-phenylenediamine, to form methylene blue (35). This technique, however, has multiple issues that make it 
unreliable for measuring biological levels including: 1) possible interference from other colored substances 
that would decrease reliability, 2) methylene blue dimer and trimer formation, 3) strong acid chemical 
pretreatment (releases sulfide from iron-sulfur centers that grossly inflate values) and 4) low sensitivity at 
low (<1 µM) H2S concentrations(it measures H2S as well as other sulfur-containing species such as 
hydrosulfide ions, sulfide, etc.) and 5) it cannot be used for continuous measurements of H2S under 
physiological conditions in real-time or with simultaneous measurement of O2, making this method less than 
optimal for measurement(35, 79, 80). With the strongly acidic conditions used for this technique, large 
sulfide concentrations in biological samples are liberated thus causing measurements to be inaccurately high.  
Monobromobimane Method 
The monobromobimane (MBB) method coupled with reverse phase high-performance liquid 
chromatography measures H2S at physiological pH and hence provides smaller numbers (79, 80). Sulfide 
derivatization occurs via MBB to form sulfide-dibimane. This relatively new methodology is a useful and 
sensitive quantitative method to measure all biochemical forms of sulfide. Disadvantages to the MBB 
method include: 1) light sensitivity (MBB is light-sensitive reagent; derivatization should be performed in 
the dark), and 2) H2S binds to glass, therefore high-quality polypropylene plastic tubes need to be used for 
preparation of samples. Additionally, chemical derivatization reactions are heavily influenced by pH, time, 
oxygen tension and volatilization all of which affect sample H2S concentration.  Also, due to irreversible 
sulfide binding or shifts in phase transition equilibria, these methods potentially can liberate loosely bound 
sulfide.  
Ion Selective Electrodes 
Sulfide-ion electrodes have also been developed that measure S2- within biological samples. 
Measurement accuracy, however, is also not without error. To form S2-, a strong alkaline solution must be 
used (pH>11) as the antioxidant buffer to drive equilibrium of H2S, HS- and S2- to S2-. The buffer promotes 
hydroxyl replacement of cysteine sulfur producing erroneously high sulfide concentrations that increase over 
time (81). Similarly, to other methods, measurement accuracy is dependent on maintaining a consistent and 
accurate pH and other biomolecules within the sample may interfere with measurement (such as thiols). 
Additionally, similarly to the methylene blue assay, it cannot be used for real-time analysis of H2S, with 
living tissue or for simultaneous measurement with O2.  
Gas Chromatography  
Gas chromatography (GC) is another analytical method used to measure physiological sulfide levels.  
However, it may liberate loosely-bound sulfide during phase transition equilibrium and falsely elevate H2S 
measurements.  It relies on equilibration of H2S between the liquid sample and gas phase measured 
following GC separation(82). Studies using GC have had variable results depending on methodology. 
Certain reports denote being able to detect sulfur at levels of 0.5 picograms with detectable ranges spanning 
four orders of magnitude(82). Similarly, to other current methods, limitations include instrumental 
parameters such as column type, injection volume and mode, as well as gas flow rate(82). While is it more 
sensitive than the methylene blue assay and ion selective electrodes, it is also unable to provide real-time 
measurements of H2S (80).  
Polarographic (Amperometric) Electrode 
To overcome the interference from other biomolecules within the samples and the requirement for 
frequent reconditioning as was seen with the ion selective electrode, the amperometric electrode was 
developed to protect the cathode, anode and electrolytes from solution constituents and more accurately 
measure H2S. This H2S specific electrode operates similarly to the standard Clark O2 electrode with an H2S 
gas specific membrane and polarizing voltage. The electrode is used with unadulterated samples and may be 
used for continuous monitoring of plasma H2S in unanesthetized animals(80). It directly measures the 
concentrations of dissolved H2S gas in real time with a detection limit of 10-20 nanomolar (nM) H2S gas or 
~100-200 nM total sulfide(80). Disadvantages to use of the amperometric electrodes include: 1) its ability to 
consume sulfide causing inaccurate measurements of H2S, 2) pressure and temperature sensitivity, and 3) 
prone to drift requiring frequent calibration(81).  
Fluorescent Probes 
The most recent and novel tool to measure H2S has been the development of fluorescent sulfide 
probes. This new easy-to-use technology provides immediate H2S detection in both living cells and organ 
tissues(83). It has been found previously that H2S itself has reducing ability and is able to change from the 
oxidation state of sulfur of -2 (H2S) to 0 (S) via reducing azide and nitro groups(83). Using this knowledge, 
novel fluorescent probes have been developed. The first two probes developed were azide-caged rhodamine 
analogs. When these probes were exposed to H2S, the azide would be reduced to amine on the probe to 
generate a highly fluorescent rhodamine product(84). Other azide-based probes have also been developed to 
target specific organelles such as mitochondria(85) or lysosomes(86). Additionally, like the azide group, 
nitro groups, nucleophilic reactions and metal-sulfide precipitations can also be reduced by H2S and used as 
part of fluorescent probes to determine H2S concentration(87). Potential down falls of this technology are 
that few can be applied to real biological detection due to slow reaction rate and/or low sensitivity. With 
these probes, it may take over an hour to achieve maximum fluorescence.  Additionally, selectivity has been 
largely unaddressed. There may be unidentified compounds, such as polysulfides, that react with the 
fluorescent probes as well as or better than H2S that have yet to be identified in the screening process. 
All of the above methodologies have their own strengths and weaknesses. With translating our H2S 
knowledge and applications from “bench to bedside”, it will become even more crucial to find a reliable, 
accurate, rapid and reproducible way to measure H2S within biological systems. 
CLINICAL ADMINISTRATION OF H2S FOR TREATMENT OF ISCHEMIA 
Research surrounding H2S has become quite popular over the last decade, most notably due to its 
potential vasodiliatory and cytoprotective properties.  These effects make H2S a potential agent for therapy 
in ischemic diseases.  In fact, many different H2S donor drugs have been created to harness the beneficial 
properties of the gas.  These H2S donors aim to mimic H2S production under physiologic conditions or 
diseased states. Although H2S in these medications is biologically active, its function may be inconsistent 
depending on its concentration.  
Problems with many H2S donors include an uncontrolled pattern of release, an unclear mechanism of 
action, and unknown by-product profiles. At present, it is difficult to define a universal best donor for all 
pathological applications. Difficulties with creating an optimal donor include considerations and 
physiological effects of H2S by-products. These effects are different based on donor, H2S releasing 
capabilities and cross-reactivity.  An ideal therapeutic H2S donor for clinical application will have the ability 
to be easily measured, to work locally without systemic effects, to have controlled and sustained release, and 
will have a minimal toxic side effect profile.  Herein, we discuss and review some of the most common 
currently available H2S donor medications (Table 1).  
Sulfide Salts 
Sodium sulfide and sodium hydrosulfide are two widely used inorganic sulfide salts in H2S research. 
Sulfide salts have the advantage of boosting H2S concentration fast. They are also “clean” donors, meaning 
that they do not produce by-products from H2S release. However, the major problem is that release is 
uncontrollable. Both inorganic substances release H2S immediately and completely as soon as they are 
dissolved in aqueous buffers. Furthermore, because H2S is a gaseous molecule, it can be quickly lost 
secondary to volatilization in an open stock solution. Previous studies have found the half-life of sulfide loss 
to be approximately 5 minutes (88). Lastly, there is a lack of understanding of the long term effects.  
Hydrogen Sulfide Gas 
H2S gas has been used to induce a suspended animation state in mice in which exposure to 80 ppm 
decreased metabolic rate via reduction of oxygen consumption and carbon dioxide output (29). This 
hibernation state revealed promising effects of H2S gas in mice but failed in large animals such as sheep and 
piglets(25, 89). Additionally, H2S gas has not been considered to be an ideal source due to difficulties in 
obtaining precisely controlled concentrations as well as potential toxic impacts of excess H2S gas exposure.  
Slow Releasing H2S Donor 
There are many organic substances currently under investigation. Most notably is the slow-releasing, 
H2S donor, GYY4137, a derivative of Lawesson’s reagent. It has sustained release in aqueous solution and 
releases H2S very slowly via what is likely to be hydrolysis. It has been found to be pH and temperature 
dependent with greater release in acidic environments and at higher temperatures. It induces vasorelaxation 
and decreased blood pressure(90). It has been found to reduce inflammation in LPS-stimulated macrophages, 
while limiting tissue damage, sepsis-induced hypotension, and production of pro-inflammatory markers in 
certain in vivo models (56, 91). Although it has been widely studied, the by-product profile has yet to be 
fully elucidated.  
1,2-Dithiole-3-Thiones 
1,2-Dithiole-3-thiones are novel H2S-releasing donors with an unclear mechanism of action. H2S is 
produced by hydrolysis when 1,2-Dithiole-3-thiones are heated (92).  1,2-Dithiole-3-thiones have been used 
to make hybrid drugs by coupling it with parent nonsteroidal anti-inflammatory drugs (NSAIDs). As such, 
many hybrid drugs (H2S-NSAIDs) have been made: ACS15 (Diclofenac), ATB-429 (Mesalamine), SH-SUL 
(Sulindac), HS-NAP (Naproxen), ACS14 (Aspirin), and HS-IBU (Ibuprofen)(93).  
Side effect profiles of the hybrid drugs also appear to be better than the parent drugs, yielding 
potential promise for clinical translation.  For example, studies found that seven days of aspirin therapy 
yielded significant hemorrhagic gastritis in rats given only aspirin.  However, in rats given the H2S-releasing 
aspirin hybrid, ACS14 did not exhibit this gastritis (93). These findings were thought to occur as a result of 
down regulation of oxidative stress.  Studies found an up-regulation of heme oxygenase 1 promoter activity 
with ACS14 while aspirin alone had no such activity. A similar study was performed with the diclofenac 
hybrid, ACS15, in which decreased gastric and intestinal mucosal damage was observed.  In addition, 
greater inhibition of TNF-α expression and decreased leukocyte adherence to vascular endothelium was also 
observed with the use of ACS15 compared to diclofenac (93). Similarly, ACS15 was also found to decrease 
lung inflammation in the setting of acute pancreatitis through significantly reduced MPO activity (94).   
Finally, the H2S-mesalamine hybrid, ATB-429, was found to be more effective in decreasing the severity of 
colitis and the production of pro-inflammatory cytokines in mouse models of this disease.  
Although 1,2-Dithiole-3-thiones are thought to be H2S donors, the extent of the effects actually 
related to H2S has not been fully elucidated. Other studies suggest that in vivo elevations of glutathione 
found with use of 1,2-Dithiole-3-thiones could also be involved in the demonstrated effects (93). 
Additionally, they are known to participate in electrophilic reactionsand the conversion of molecular oxygen 
to reactive oxygen radicals. Therefore, more information is needed on mechanisms of action of these drugs 
prior to widespread application.  
Garlic-Derived Hydrogen Sulfide  
Garlic is known to be rich in sulfur-containing compounds and has demonstrated both anti-
inflammatory and cardioprotective affects secondary to its H2S-releasing capability. Allicin (diallyl 
thiosulfinate) is the best characterized compound in garlic. In aqueous solution, it decomposes to diallyl 
sulfide, diallyl disulfide and diallyl trisulfide(95). Additionally, recent literature suggests that H2S release 
from garlic oil is thiol-mediated while polysulfides are readily detected in garlic oil alone (96). 
Administration of garlic oil rapidly increases intracellular polysulfide with minimal effects on H2S 
suggesting that polysulfides, not H2S, may be the actual mediator in physiological signaling. Human red 
blood cells are able to convert these garlic-derived organic polysulfides into H2S thus promoting vasodilation 
in blood vessels(97). Garlic is also well known to be protective against ischemic injury in many different 
organ systems (renal, hepatic, cardiac, cerebral and pulmonary)(96, 97). Garlic and garlic-derived sulfur 
compounds exhibit concentration-dependent vasorelaxation most likely due to the presence of polysulfides.  
FUTURE DIRECTIONS 
This review of H2S suggests that H2S-related drugs may be a novel therapy to halt disease 
progression in the setting of ischemia. H2S is an endogenous gaseous mediator that plays a key role in a 
broad range of physiological functions including vasorelaxation, angiogenesis, cell protection, and 
inflammation. While many of these protective benefits have been attributed to the production of H2S, there is 
suggestion that some of the observed benefits could be related to the release of other sulfide mediators such 
as polysulfides or persulfides. Additionally, the possibility of H2S generation and metabolism via another 
pathway is possible and the physiologic triggers that induce production of H2S, persulfides and polysulfides 
endogenously to maintain local levels remains unknown. Understanding the mechanisms controlling the 
actual concentrations of H2S in circulation and in tissues becomes paramount. In this regard, further 
investigation into the role of other sulfide mediators in end-organ ischemia is warranted along with inquiry 
into additional H2S pathways.  
In the setting of end-organ ischemia, an H2S-releasing drug could prove to be a novel therapy where 
current abilities to reverse damage are limited. A number of slow-releasing H2S drugs and hybrid H2S drugs 
have been developed and found to have effectiveness in various models. However, with many of these drugs, 
byproducts are still largely unknown. Additionally, the pharmacokinetics, pharmacodynamics, efficacy and 
toxicity profiles of many of these hybrids remain unanswered. Prior to H2S therapy being brought to the 
forefront of clinical use, it is essential to have precise control of H2S release so that we are able to emulate 
endogenous H2S production. Additionally, it is also crucial to determine the most effective concentration and 
relevant route of administration. The ideal H2S-releasing drug should work locally without systemic effects, 
have controlled and sustained release, and limited side effects. Lastly, further development of these donors 
requires a way to accurately and consistently measure absolute concentrations of H2S in the circulation and 
in tissues.  
While multiple avenues of H2S measurement have been utilized, all of them come with inherent 
flaws. Hydrogen sulfide’s volatile nature makes measurement exceedingly difficult. Previous work has 
demonstrated that with intravenous administration, H2S is rapidly taken in and bound to other thiols or 
carbon and/or coordinated with metals(39). As we continue to make strides of improvement with advancing 
techniques for H2S measurement in biological samples, there is still no consensus on the most acceptable and 
reliable technique. Additionally, with the uncertainty of all known “key players” of H2S protection (namely 
free H2S gas versus sulfane sulfurs (persulfides, polysulfides, thiosulfate, etc.)); a way to improve accuracy 
and reliability in measurement of absolute concentrations of all H2S is paramount. Investigations into the 
potential biological activity of other sulfur containing molecules such as persulfides and others confirm that 
a way to more accurately and consistently measure H2S in the blood may be through measurement of total 
sulfide rather than the gas itself. As previously described by Shen et al. and as described above, using the 
monobromobimane method coupled with RP-HPLC (which involves liberation, trapping and derivatization 
of H2S), may allow for repeatable measurement of total sulfide concentrations in various biological 
specimens(98). Once a consensus is reached on the best way to measure endogenous levels of H2S, known 
benefits of H2S therapies may be translated into a clinical setting for further investigation.  
CONCLUSION 
End-organ ischemia continues to be a complex pathophysiological process involving many factors 
including oxidative stress and systemic inflammation.  The design of novel therapies to treat these conditions 
is therefore paramount.   Hydrogen sulfide is one such potential option.  As a potent vasodilatory and 
cytoprotective agent, H2S exhibits a number of biological properties that make it an attractive agent for 
therapy.  However, prior to widespread clinical use, its safety profiles and mechanisms of action need to be 
further delineated, and an accurate and rapid method of assessment needs to be created.  Further studies on 
these areas of interest will allow for more rapid translation to the care of critically ill patients with ischemia. 
REFERENCES 
1. Wang R: Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol
Rev 92:791-896, 2012.
2. Stein A, Bailey SM: Redox Biology of Hydrogen Sulfide: Implications for Physiology,
Pathophysiology, and Pharmacology. Redox Biol 1:32-39, 2013.
3. Liu H, Bai XB, Shi S, Cao YX: Hydrogen sulfide protects from intestinal ischaemia-reperfusion
injury in rats. J Pharm Pharmacol 61:207-212, 2009.
4. Wang Y, Jia J, Ao G, Hu L, Liu H, Xiao Y, Du H, Alkayed NJ, Liu CF, Cheng J: Hydrogen sulfide
protects blood-brain barrier integrity following cerebral ischemia. J Neurochem 129:827-838, 2014.
5. Ansari SB, Kurian GA: Hydrogen sulfide modulates sub-cellular susceptibility to oxidative stress
induced by myocardial ischemic reperfusion injury. Chem Biol Interact 252:28-35, 2016.
6. Olas B: Hydrogen sulfide in signaling pathways. Clinica chimica acta; international journal of
clinical chemistry 439:212-218, 2015.
7. Hosoki R, Matsuki N, Kimura H: The possible role of hydrogen sulfide as an endogenous smooth
muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun 237:527-531, 1997.
8. Wu D, Wang J, Li H, Xue M, Ji A, Li Y: Role of Hydrogen Sulfide in Ischemia-Reperfusion Injury.
Oxid Med Cell Longev 2015:186908, 2015.
9. Saha S, Chakraborty PK, Xiong X, Dwivedi SK, Mustafi SB, Leigh NR, Ramchandran R, Mukherjee
P, Bhattacharya R: Cystathionine beta-synthase regulates endothelial function via protein S-
sulfhydration. FASEB J 30:441-456, 2016.
10. Kimura H: The physiological role of hydrogen sulfide and beyond. Nitric Oxide 41:4-10, 2014.
11. Wallace JL, Wang R: Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous
gasotransmitter. Nat Rev Drug Discov 14:329-345, 2015.
12. Xu S, Liu Z, Liu P: Targeting hydrogen sulfide as a promising therapeutic strategy for
atherosclerosis. Int J Cardiol 172:313-317, 2014.
13. Fu M, Zhang W, Wu L, Yang G, Li H, Wang R: Hydrogen sulfide (H2S) metabolism in
mitochondria and its regulatory role in energy production. Proc Natl Acad Sci USA 109:2943-2948,
2012.
14. Shibuya N, Koike S, Tanaka M, Ishigami-Yuasa M, Kimura Y, Ogasawara Y, Fukui K, Nagahara N,
Kimura H: A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian
cells. Nat Commun 4:1366, 2013.
15. Toohey JI: Sulphane sulphur in biological systems: a possible regulatory role. Biochem J 264:625-
632, 1989.
16. Toohey JI: Sulfur signaling: Is the agent sulfide or sulfane? (413:1-7, 2011). Analytical Biochemistry
415:221, 2011.
17. Daniels KM, Stipanuk MH: The effect of dietary cysteine level on cysteine metabolism in rats. J Nutr
112:2130-2141, 1982.
18. Ishigami M, Hiraki K, Umemura K, Ogasawara Y, Ishii K, Kimura H: A source of hydrogen sulfide
and a mechanism of its release in the brain. Antioxid Redox Signal 11:205-214, 2009.
19. Olson KR, Straub KD: The Role of Hydrogen Sulfide in Evolution and the Evolution of Hydrogen
Sulfide in Metabolism and Signaling. Physiology (Bethesda) 31:60-72, 2016.
20. Paul BD, Snyder SH: Protein sulfhydration. Methods Enzymol 555:79-90, 2015.
21. Kimura H: Hydrogen sulfide and polysulfides as biological mediators. Molecules 19:16146-16157,
2014.
22. Olson KR, Deleon ER, Gao Y, Hurley K, Sadauskas V, Batz C, Stoy GF: Thiosulfate: a readily
accessible source of hydrogen sulfide in oxygen sensing. Am J Physiol Regul Integr Comp Physiol
305:R592-603, 2013.
23. Mitsuhashi H, Yamashita S, Ikeuchi H, Kuroiwa T, Kaneko Y, Hiromura K, Ueki K, Nojima Y:
Oxidative stress-dependent conversion of hydrogen sulfide to sulfite by activated neutrophils. Shock
24:529-534, 2005.
24. Szabo C, Ransy C, Modis K, Andriamihaja M, Murghes B, Coletta C, Olah G, Yanagi K, Bouillaud
F: Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and
physiological mechanisms. Br J Pharmacol 171:2099-2122, 2014.
25. Derwall M, Francis RC, Kida K, Bougaki M, Crimi E, Adrie C, Zapol WM, Ichinose F:
Administration of hydrogen sulfide via extracorporeal membrane lung ventilation in sheep with
partial cardiopulmonary bypass perfusion: a proof of concept study on metabolic and vasomotor
effects. Crit Care 15:R51, 2011.
26. Szabo C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917-935, 2007.
27. Dhaese I, Van Colen I, Lefebvre RA: Mechanisms of action of hydrogen sulfide in relaxation of
mouse distal colonic smooth muscle. Eur J Pharmacol 628:179-186, 2010.
28. Gallego D, Clave P, Donovan J, Rahmati R, Grundy D, Jimenez M, Beyak MJ: The gaseous
mediator, hydrogen sulphide, inhibits in vitro motor patterns in the human, rat and mouse colon and
jejunum. Neurogastroenterol Motil 20:1306-1316, 2008.
29. Blackstone E, Morrison M, Roth MB: H2S induces a suspended animation-like state in mice. Science
308:518, 2005.
30. Simon F, Giudici R, Duy CN, Schelzig H, Oter S, Groger M, Wachter U, Vogt J, Speit G, Szabo C et
al: Hemodynamic and metabolic effects of hydrogen sulfide during porcine ischemia/reperfusion
injury. Shock 30:359-364, 2008.
31. Blackstone E, Roth MB: Suspended animation-like state protects mice from lethal hypoxia. Shock
27:370-372, 2007.
32. Dziewiatkowski DD: Fate of ingested sulfide sulfur labeled with radioactive sulfur in the rat. The
Journal of biological chemistry 161:723-729, 1945.
33. Insko MA, Deckwerth TL, Hill P, Toombs CF, Szabo C: Detection of exhaled hydrogen sulphide gas
in rats exposed to intravenous sodium sulphide. Br J Pharmacol 157:944-951, 2009.
34. Baxter CF, Van Reen R: The oxidation of sulfide to thiosulfate by metalloprotein complexes and by
ferritin. Biochim Biophys Acta 28:573-578, 1958.
35. Li L, Rose P, Moore PK: Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol 51:169-
187, 2011.
36. Zhao W, Zhang J, Lu Y, Wang R: The vasorelaxant effect of H(2)S as a novel endogenous gaseous
K(ATP) channel opener. EMBO J 20:6008-6016, 2001.
37. Cheng Y, Ndisang JF, Tang G, Cao K, Wang R: Hydrogen sulfide-induced relaxation of resistance
mesenteric artery beds of rats. American journal of physiology Heart and circulatory physiology
287:H2316-2323, 2004.
38. Siebert N, Cantre D, Eipel C, Vollmar B: H2S contributes to the hepatic arterial buffer response and
mediates vasorelaxation of the hepatic artery via activation of K(ATP) channels. Am J Physiol
Gastrointest Liver Physiol 295:G1266-1273, 2008.
39. Filipovic MR: Persulfidation (S-sulfhydration) and H2S. Handb Exp Pharmacol 230:29-59, 2015.
40. Sun Y, Huang Y, Zhang R, Chen Q, Chen J, Zong Y, Liu J, Feng S, Liu AD, Holmberg L et al:
Hydrogen sulfide upregulates KATP channel expression in vascular smooth muscle cells of
spontaneously hypertensive rats. J Mol Med (Berl) 93:439-455, 2015.
41. Jackson-Weaver O, Osmond JM, Riddle MA, Naik JS, Gonzalez Bosc LV, Walker BR, Kanagy NL:
Hydrogen sulfide dilates rat mesenteric arteries by activating endothelial large-conductance Ca(2)(+)-
activated K(+) channels and smooth muscle Ca(2)(+) sparks. Am J Physiol Heart Circ Physiol
304:H1446-1454, 2013.
42. Roy A, Khan AH, Islam MT, Prieto MC, Majid DS: Interdependency of cystathione gamma-lyase
and cystathione beta-synthase in hydrogen sulfide-induced blood pressure regulation in rats. Am J
Hypertens 25:74-81, 2012.
43. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S et al: H2S as
a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase.
Science 322:587-590, 2008.
44. Pavoni V, Nicoletti P, Benemei S, Materazzi S, Perna F, Romagnoli S, Chelazzi C, Zagli G, Coratti
A: Effects of hydrogen sulfide (H2S) on mesenteric perfusion in experimental induced intestinal
ischemia in a porcine model. Heart Lung Vessel 7:231-237, 2015.
45. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, Jeschke MG, Branski
LK, Herndon DN, Wang R et al: Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc
Natl Acad Sci U S A 106:21972-21977, 2009.
46. Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, Zhu YC: The novel proangiogenic effect of hydrogen
sulfide is dependent on Akt phosphorylation. Cardiovasc Res 76:29-40, 2007.
47. Tao BB, Liu SY, Zhang CC, Fu W, Cai WJ, Wang Y, Shen Q, Wang MJ, Chen Y, Zhang LJ et al:
VEGFR2 functions as an H2S-targeting receptor protein kinase with its novel Cys1045-Cys1024
disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular
endothelial cells. Antioxid Redox Signal 19:448-464, 2013.
48. Du J, Hui Y, Cheung Y, Bin G, Jiang H, Chen X, Tang C: The possible role of hydrogen sulfide as a
smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels 19:75-80, 2004.
49. Meng QH, Yang G, Yang W, Jiang B, Wu L, Wang R: Protective effect of hydrogen sulfide on
balloon injury-induced neointima hyperplasia in rat carotid arteries. Am J Pathol 170:1406-1414,
2007.
50. Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, Zhu YC: The hydrogen sulfide donor NaHS promotes
angiogenesis in a rat model of hind limb ischemia. Antioxid Redox Signal 12:1065-1077, 2010.
51. Qipshidze N, Metreveli N, Mishra PK, Lominadze D, Tyagi SC: Hydrogen sulfide mitigates cardiac
remodeling during myocardial infarction via improvement of angiogenesis. Int J Biol Sci  8:430-441,
2012.
52. Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Modis K, Panopoulos P, Asimakopoulou A, Gero
D, Sharina I, Martin E et al: Hydrogen sulfide and nitric oxide are mutually dependent in the
regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci USA
109:9161-9166, 2012.
53. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL: Hydrogen sulfide is an
endogenous modulator of leukocyte-mediated inflammation. FASEB J 20:2118-2120, 2006.
54. Mustafa AK, Gadalla MM, Sen N, Kim S, Mu W, Gazi SK, Barrow RK, Yang G, Wang R, Snyder
SH: H2S signals through protein S-sulfhydration. Sci Signal 2:ra72, 2009.
55. Sen N, Paul BD, Gadalla MM, Mustafa AK, Sen T, Xu R, Kim S, Snyder SH: Hydrogen sulfide-
linked sulfhydration of NF-kappaB mediates its antiapoptotic actions. Mol Cell 45:13-24, 2012.
56. Whiteman M, Li L, Rose P, Tan CH, Parkinson DB, Moore PK: The effect of hydrogen sulfide
donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages.
Antioxid Redox Signal 12:1147-1154, 2010.
57. Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith
RN, Csizmadia E et al: Carbon monoxide suppresses arteriosclerotic lesions associated with chronic
graft rejection and with balloon injury. Nat Med 9:183-190, 2003.
58. Zhang H, Zhi L, Moore PK, Bhatia M: Role of hydrogen sulfide in cecal ligation and puncture-
induced sepsis in the mouse. Am J Physiol Lung Cell Mol Physiol 290:L1193-1201, 2006.
59. Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ, Anuar FB, Whiteman M, Salto-Tellez M,
Moore PK: Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the
mouse. FASEB J 19:1196-1198, 2005.
60. Ahmad A, Druzhyna N, Szabo C: Delayed Treatment with Sodium Hydrosulfide Improves Regional
Blood Flow and Alleviates Cecal Ligation and Puncture (CLP) - Induced Septic Shock. Shock
46:183-193, 2016.
61. Mard SA, Neisi N, Solgi G, Hassanpour M, Darbor M, Maleki M: Gastroprotective effect of NaHS
against mucosal lesions induced by ischemia-reperfusion injury in rat. Dig Dis Sci 57:1496-1503,
2012.
62. Zhang H, Zhi L, Moochhala SM, Moore PK, Bhatia M: Endogenous hydrogen sulfide regulates
leukocyte trafficking in cecal ligation and puncture-induced sepsis. J Leukoc Biol 82:894-905, 2007.
63. Xie YH, Zhang N, Li LF, Zhang QZ, Xie LJ, Jiang H, Li LP, Hao N, Zhang JX: Hydrogen sulfide
reduces regional myocardial ischemia injury through protection of mitochondrial function. Mol Med
Rep 10:1907-1914, 2014.
64. Xiao J, Zhu X, Kang B, Xu J, Wu L, Hong J, Zhang Y, Ni X, Wang Z: Hydrogen Sulfide Attenuates
Myocardial Hypoxia-Reoxygenation Injury by Inhibiting Autophagy via mTOR Activation. Cell
Physiol Biochem 37:2444-2453, 2015.
65. Sivarajah A, Collino M, Yasin M, Benetti E, Gallicchio M, Mazzon E, Cuzzocrea S, Fantozzi R,
Thiemermann C: Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of
regional myocardial I/R. Shock 31:267-274, 2009.
66. Wagner F, Asfar P, Calzia E, Radermacher P, Szabo C: Bench-to-bedside review: Hydrogen sulfide--
the third gaseous transmitter: applications for critical care. Crit Care 13:213, 2009.
67. Dongo E, Hornyak I, Benko Z, Kiss L: The cardioprotective potential of hydrogen sulfide in
myocardial ischemia/reperfusion injury (review). Acta Physiol Hung 98:369-381, 2011.
68. Ahmad A, Olah G, Szczesny B, Wood ME, Whiteman M, Szabo C: AP39, A Mitochondrially
Targeted Hydrogen Sulfide Donor, Exerts Protective Effects in Renal Epithelial Cells Subjected to
Oxidative Stress in Vitro and in Acute Renal Injury in Vivo. Shock 45:88-97, 2016.
69. Han SJ, Kim JI, Park JW, Park KM: Hydrogen sulfide accelerates the recovery of kidney tubules
after renal ischemia/reperfusion injury. Nephrol Dial Transplant 30:1497-1506, 2015.
70. Stenzel T, Weidgang C, Wagner K, Wagner F, Groger M, Weber S, Stahl B, Wachter U, Vogt J,
Calzia E et al: Association of Kidney Tissue Barrier Disrupture and Renal Dysfunction in
Resuscitated Murine Septic Shock. Shock 46:398-404, 2016.
71. Simon F, Scheuerle A, Groger M, Stahl B, Wachter U, Vogt J, Speit G, Hauser B, Moller P, Calzia E
et al: Effects of intravenous sulfide during porcine aortic occlusion-induced kidney
ischemia/reperfusion injury. Shock 35:156-163, 2011.
72. Wang R: Hydrogen sulfide: a new EDRF. Kidney Int 76:700-704, 2009.
73. Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, Barodka VM, Gazi FK, Barrow
RK, Wang R et al: Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates
potassium channels. Circ Res 109:1259-1268, 2011.
74. Altaany Z, Ju Y, Yang G, Wang R: The coordination of S-sulfhydration, S-nitrosylation, and
phosphorylation of endothelial nitric oxide synthase by hydrogen sulfide. Sci Signal 7:ra87, 2014.
75. Rong-na L, Xiang-jun Z, Yu-han C, Ling-qiao L, Gang H: Interaction between hydrogen sulfide and
nitric oxide on cardiac protection in rats with metabolic syndrome. Zhongguo Yi Xue Ke Xue Yuan
Xue Bao 33:25-32, 2011.
76. Eberhardt M, Dux M, Namer B, Miljkovic J, Cordasic N, Will C, Kichko TI, de la Roche J, Fischer
M, Suarez SA et al: H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine
HNO-TRPA1-CGRP signalling pathway. Nat Commun 5:4381, 2014.
77. Pozsgai G, Hajna Z, Bagoly T, Boros M, Kemeny A, Materazzi S, Nassini R, Helyes Z, Szolcsanyi J,
Pinter E: The role of transient receptor potential ankyrin 1 (TRPA1) receptor activation in hydrogen-
sulphide-induced CGRP-release and vasodilation. Eur J Pharmacol 689:56-64, 2012.
78. Olson KR: Is hydrogen sulfide a circulating "gasotransmitter" in vertebrate blood? Biochim Biophys
Acta 1787:856-863, 2009.
79. Olson KR, DeLeon ER, Liu F: Controversies and conundrums in hydrogen sulfide biology. Nitric
Oxide 41:11-26, 2014.
80. Olson KR: A practical look at the chemistry and biology of hydrogen sulfide. Antioxid Redox Signal
17:32-44, 2012.
81. Whitfield NL, Kreimier EL, Verdial FC, Skovgaard N, Olson KR: Reappraisal of H2S/sulfide
concentration in vertebrate blood and its potential significance in ischemic preconditioning and
vascular signaling. Am J Physiol Regul Integr Comp Physiol 294:R1930-1937, 2008.
82. Vitvitsky V, Banerjee R: H2S analysis in biological samples using gas chromatography with sulfur
chemiluminescence detection. Methods Enzymol 554:111-123, 2015.
83. Shimamoto K, Hanaoka K: Fluorescent probes for hydrogen sulfide (H2S) and sulfane sulfur and
their applications to biological studies. Nitric Oxide 46:72-79, 2015.
84. Lippert AR, New EJ, Chang CJ: Reaction-based fluorescent probes for selective imaging of
hydrogen sulfide in living cells. J Am Chem Soc 133:10078-10080, 2011.
85. Bae SK, Heo CH, Choi DJ, Sen D, Joe EH, Cho BR, Kim HM: A ratiometric two-photon fluorescent
probe reveals reduction in mitochondrial H2S production in Parkinson's disease gene knockout
astrocytes. J Am Chem Soc 135:9915-9923, 2013.
86. Yang S, Qi Y, Liu C, Wang Y, Zhao Y, Wang L, Li J, Tan W, Yang R: Design of a simultaneous
target and location-activatable fluorescent probe for visualizing hydrogen sulfide in lysosomes. Anal
Chem 86:7508-7515, 2014.
87. Montoya LA, Pluth MD: Selective turn-on fluorescent probes for imaging hydrogen sulfide in living
cells. Chem Commun (Camb) 48:4767-4769, 2012.
88. DeLeon ER, Stoy GF, Olson KR: Passive loss of hydrogen sulfide in biological experiments. Anal
Biochem 421:203-207, 2012.
89. Li J, Zhang G, Cai S, Redington AN: Effect of inhaled hydrogen sulfide on metabolic responses in
anesthetized, paralyzed, and mechanically ventilated piglets. Pediatr Crit Care Med 9:110-112, 2008.
90. Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, Zhao Y, Baskar R, Tan CH, Moore PK:
Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new
insights into the biology of hydrogen sulfide. Circulation 117:2351-2360, 2008.
91. Li L, Salto-Tellez M, Tan CH, Whiteman M, Moore PK: GYY4137, a novel hydrogen sulfide-
releasing molecule, protects against endotoxic shock in the rat. Free Radic Biol Med 47:103-113,
2009.
92. Qandil AM: Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a
critical review. Int J Mol Sci 13:17244-17274, 2012.
93. Zhao Y, Biggs TD, Xian M: Hydrogen sulfide (H2S) releasing agents: chemistry and biological
applications. Chem Commun (Camb) 50:11788-11805, 2014.
94. Bhatia M, Sidhapuriwala JN, Sparatore A, Moore PK: Treatment with H2S-releasing diclofenac
protects mice against acute pancreatitis-associated lung injury. Shock 29:84-88, 2008.
95. Amagase H: Clarifying the real bioactive constituents of garlic. J Nutr 136:716S-725S, 2006.
96. DeLeon ER, Gao Y, Huang E, Olson KR: Garlic oil polysulfides: H2S- and O2-independent
prooxidants in buffer and antioxidants in cells. Am J Physiol Regul Integr Comp Physiol310:R1212-
1225, 2016.
97. Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, Darley-Usmar VM, Doeller
JE, Kraus DW: Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci U S A
104:17977-17982, 2007.
98. Shen X, Peter EA, Bir S, Wang R, Kevil CG: Analytical measurement of discrete hydrogen sulfide
pools in biological specimens. Free Radic Biol Med 52:2276-2283, 2012.
99. Tokuda K, Kida K, Marutani E, Crimi E, Bougaki M, Khatri A, Kimura H, Ichinose F: Inhaled
hydrogen sulfide prevents endotoxin-induced systemic inflammation and improves survival by
altering sulfide metabolism in mice. Antioxid Redox Signal 17:11-21, 2012.
100. Haouzi P, Bell HJ, Notet V, Bihain B: Comparison of the metabolic and ventilatory response to
hypoxia and H2S in unsedated mice and rats. Respir Physiol Neurobiol 167:316-322, 2009.
101. Wei X, Zhang B, Cheng L, Chi M, Deng L, Pan H, Yao X, Wang G: Hydrogen sulfide induces
neuroprotection against experimental stroke in rats by down-regulation of AQP4 via activating PKC.
Brain Res 1622:292-299, 2015.
102. Wei X, Zhang B, Zhang Y, Li H, Cheng L, Zhao X, Yin J, Wang G: Hydrogen Sulfide Inhalation
Improves Neurological Outcome via NF-kappaB-Mediated Inflammatory Pathway in a Rat Model of
Cardiac Arrest and Resuscitation. Cell Physiol Biochem 36:1527-1538, 2015.
103. Biermann J, Lagreze WA, Schallner N, Schwer CI, Goebel U: Inhalative preconditioning with
hydrogen sulfide attenuated apoptosis after retinal ischemia/reperfusion injury. Mol Vis 17:1275-
1286, 2011.
104. Stein A, Mao Z, Morrison JP, Fanucchi MV, Postlethwait EM, Patel RP, Kraus DW, Doeller JE,
Bailey SM: Metabolic and cardiac signaling effects of inhaled hydrogen sulfide and low oxygen in
male rats. J Appl Physiol (1985) 112:1659-1669, 2012.
105. Wei X, Duan L, Bai L, Tian M, Li W, Zhang B: Effects of exogenous hydrogen sulfide on brain
metabolism and early neurological function in rabbits after cardiac arrest. Intensive Care Med
38:1877-1885, 2012.
106. Li N, Wang MJ, Jin S, Bai YD, Hou CL, Ma FF, Li XH, Zhu YC: The H2S Donor NaHS Changes
the Expression Pattern of H2S-Producing Enzymes after Myocardial Infarction. Oxid Med Cell
Longev 2016:6492469, 2016.
107. Li B, Lee C, Martin Z, Li X, Koike Y, Hock A, Zani-Ruttenstock E, Zani A, Pierro A: Intestinal
epithelial injury induced by maternal separation is protected by hydrogen sulfide. J Pediatr Surg
52:40-44, 2017.
108. Shimada S, Fukai M, Wakayama K, Ishikawa T, Kobayashi N, Kimura T, Yamashita K, Kamiyama
T, Shimamura T, Taketomi A et al: Hydrogen sulfide augments survival signals in warm ischemia
and reperfusion of the mouse liver. Surg Today 45:892-903, 2015.
109. Dai HB, Ji X, Zhu SH, Hu YM, Zhang LD, Miao XL, Ma RM, Duan ML, Li WY: Hydrogen
sulphide and mild hypothermia activate the CREB signaling pathway and prevent ischemia-
reperfusion injury. BMC Anesthesiol 15:119, 2015.
110. Yu Q, Lu Z, Tao L, Yang L, Guo Y, Yang Y, Sun X, Ding Q: ROS-Dependent Neuroprotective
Effects of NaHS in Ischemia Brain Injury Involves the PARP/AIF Pathway. Cell Physiol
Biochem6:1539-1551, 2015.
111. Pan H, Xie X, Chen D, Zhang J, Zhou Y, Yang G: Protective and biogenesis effects of sodium
hydrosulfide on brain mitochondria after cardiac arrest and resuscitation. Eur J Pharmacol 741:74-
82, 2014.
112. Hu MZ, Zhou B, Mao HY, Sheng Q, Du B, Chen JL, Pang QF, Ji Y: Exogenous Hydrogen Sul fi de
Postconditioning Protects Isolated Rat Hearts From Ischemia/Reperfusion Injury Through
Sirt1/PGC-1alpha Signaling Pathway. Int Heart J 57:477-482, 2016.
113. Sun YG, Wang XY, Chen X, Shen CX, Li YG: Hydrogen sulfide improves cardiomyocytes electrical
remodeling post ischemia/reperfusion injury in rats. Int J Clin Exp Pathol 8:474-481, 2015.
114. Tu F, Li J, Wang J, Li Q, Chu W: Hydrogen sulfide protects against cognitive impairment induced by
hepatic ischemia and reperfusion via attenuating neuroinflammation. Exp Biol Med (Maywood)
241:636-643, 2016.
115. Huang X, Gao Y, Qin J, Lu S: The role of miR-34a in the hepatoprotective effect of hydrogen sulfide
on ischemia/reperfusion injury in young and old rats. PLoS One 9:e113305, 2014.
116. Ibrahim MY, Aziz NM, Kamel MY, Rifaai RA: Sodium hydrosulphide against renal
ischemia/reperfusion and the possible contribution of nitric oxide in adult male Albino rats. Bratisl
Lek Listy 116:681-688, 2015.
117. Lobb I, Davison M, Carter D, Liu W, Haig A, Gunaratnam L, Sener A: Hydrogen Sulfide Treatment
Mitigates Renal Allograft Ischemia-Reperfusion Injury during Cold Storage and Improves Early
Transplant Kidney Function and Survival Following Allogeneic Renal Transplantation. J Urol
194:1806-1815, 2015.
118. Azizi F, Seifi B, Kadkhodaee M, Ahghari P: Administration of hydrogen sulfide protects ischemia
reperfusion-induced acute kidney injury by reducing the oxidative stress. Ir J Med Sci 185:649-654,
2016.
119. Bibli SI, Andreadou I, Chatzianastasiou A, Tzimas C, Sanoudou D, Kranias E, Brouckaert P, Coletta
C, Szabo C, Kremastinos DT et al: Cardioprotection by H2S engages a cGMP-dependent protein
kinase G/phospholamban pathway. Cardiovasc Res 106:432-442, 2015.
120. Sodha NR, Clements RT, Feng J, Liu Y, Bianchi C, Horvath EM, Szabo C, Sellke FW: The effects of
therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury. Eur J
Cardiothorac Surg 33:906-913, 2008.
121. Shi H, Jing X, Wei X, Perez RG, Ren M, Zhang X, Lou H: S-allyl cysteine activates the Nrf2-
dependent antioxidant response and protects neurons against ischemic injury in vitro and in vivo. J
Neurochem 133:298-308, 2015.
122. Predmore BL, Kondo K, Bhushan S, Zlatopolsky MA, King AL, Aragon JP, Grinsfelder DB, Condit
ME, Lefer DJ: The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of
endogenous hydrogen sulfide and increasing nitric oxide bioavailability. Am J Physiol Heart Circ
Physiol 302:H2410-2418, 2012.
123. Cemil B, Gokce EC, Kahveci R, Gokce A, Aksoy N, Sargon MF, Erdogan B, Kosem B: Aged Garlic
Extract Attenuates Neuronal Injury in a Rat Model of Spinal Cord Ischemia/Reperfusion Injury. J
Med Food 19:601-606, 2016.
124. Lin JJ, Chang T, Cai WK, Zhang Z, Yang YX, Sun C, Li ZY, Li WX: Post-injury administration of
allicin attenuates ischemic brain injury through sphingosine kinase 2: In vivo and in vitro studies.
Neurochem Int 89:92-100, 2015.
125. Zhang B, Li F, Zhao W, Li J, Li Q, Wang W: Protective effects of allicin against ischemic stroke in a
rat model of middle cerebral artery occlusion. Mol Med Rep 12:3734-3738, 2015.
126. Wen YD, Zhu YZ: The Pharmacological Effects of S-Propargyl-Cysteine, a Novel Endogenous H2S-
Producing Compound. Handb Exp Pharmacol 230:325-336, 2015.
127. Shaik IH, George JM, Thekkumkara TJ, Mehvar R: Protective effects of diallyl sulfide, a garlic
constituent, on the warm hepatic ischemia-reperfusion injury in a rat model. Pharm Res 25:2231-
2242, 2008.
128. Ali SI, Alhusseini NF, Atteia HH, Idris RA, Hasan RA: Renoprotective effect of a combination of
garlic and telmisartan against ischemia/reperfusion-induced kidney injury in obese rats. Free Radic
Res 50:966-986, 2016.
129. Savas M, Yeni E, Ciftci H, Yildiz F, Gulum M, Keser BS, Verit A, Utangac M, Kocyigit A, Celik H
et al: The antioxidant role of oral administration of garlic oil on renal ischemia-reperfusion injury.
Ren Fail 32:362-367, 2010.
130. Segoviano-Murillo S, Sanchez-Gonzalez DJ, Martinez-Martinez CM, Cruz C, Maldonado PD,
Pedraza-Chaverri J: S-allylcysteine ameliorates ischemia and reperfusion induced renal damage.
Phytother Res 22:836-840, 2008.
131. Bombicz M, Priksz D, Varga B, Gesztelyi R, Kertesz A, Lengyel P, Balogh P, Csupor D, Hohmann
J, Bhattoa HP et al: Anti-Atherogenic Properties of Allium ursinum Liophylisate: Impact on
Lipoprotein Homeostasis and Cardiac Biomarkers in Hypercholesterolemic Rabbits. Int J Mol Sci 17,
2016.
132. Zhu JW, Chen T, Guan J, Liu WB, Liu J: Neuroprotective effects of allicin on spinal cord ischemia-
reperfusion injury via improvement of mitochondrial function in rabbits. Neurochem Int 61:640-648,
2012.
133. Kuo PC, Yu IC, Scofield BA, Brown DA, Curfman ET, Paraiso HC, Chang FL, Yen JH: 3H-1,2-
Dithiole-3-thione as a novel therapeutic agent for the treatment of ischemic stroke through Nrf2
defense pathway. Brain Behav Immun 62:180-192, 2017.
134. Xie H, Xu Q, Jia J, Ao G, Sun Y, Hu L, Alkayed NJ, Wang C, Cheng J: Hydrogen sulfide protects
against myocardial ischemia and reperfusion injury by activating AMP-activated protein kinase to
restore autophagic flux. Biochem Biophys Res Commun 458:632-638, 2015.
135. Cao Z, Zhu H, Zhang L, Zhao X, Zweier JL, Li Y: Antioxidants and phase 2 enzymes in
cardiomyocytes: Chemical inducibility and chemoprotection against oxidant and simulated ischemia-
reperfusion injury. Exp Biol Med (Maywood) 231:1353-1364, 2006.
136. Rossoni G, Sparatore A, Tazzari V, Manfredi B, Del Soldato P, Berti F: The hydrogen sulphide-
releasing derivative of diclofenac protects against ischaemia-reperfusion injury in the isolated rabbit
heart. Br J Pharmacol 153:100-109, 2008.
137. Chatzianastasiou A, Bibli SI, Andreadou I, Efentakis P, Kaludercic N, Wood ME, Whiteman M, Di
Lisa F, Daiber A, Manolopoulos VG et al: Cardioprotection by H2S Donors: Nitric Oxide-Dependent
and Independent Mechanisms. J Pharmacol Exp Ther 358:431-440, 2016.
138. Lilyanna S, Peh MT, Liew OW, Wang P, Moore PK, Richards AM, Martinez EC: GYY4137
attenuates remodeling, preserves cardiac function and modulates the natriuretic peptide response to
ischemia. J Mol Cell Cardiol 87:27-37, 2015.
139. Magierowski M, Magierowska K, Hubalewska-Mazgaj M, Sliwowski Z, Pajdo R, Ginter G,
Kwiecien S, Brzozowski T: Exogenous and Endogenous Hydrogen Sulfide Protects Gastric Mucosa
against the Formation and Time-Dependent Development of Ischemia/Reperfusion-Induced Acute
Lesions Progressing into Deeper Ulcerations. Molecules 22, 2017.
Fi
rea
su
cy
gure 1.  Enz
ction betw
bsequently 
steine to H2
ymatic pro
een homocy
catalyzed b
S and L-ser
duction of 
steine and
y CSE to fo
ine, while 
H2S within 
 serine to fo
rm 2-ketob
CSE conve
mammalian
rm cystath
utyrate, cy
rts L-cystein
 cells. To p
ionine and H
steine, H2O
e to H2S, p
roduce H2
2O. Cysta
 and ammo
yruvate and
S, CBS cata
thionine an
nia. CBS th
 ammonia
lyzes the 
d H2O are 
en convert
.  
s L-
Fi
me
ca
gure 2. H2S
diator of a
scade, cell 
 has a numb
ngiogenesis
death, and a
er of bene
 and vasore
poptosis.  
ficial prope
laxation. A
rties in the 
dditionally
setting of is
, it has been
chemia. It 
 found to d
has been fo
ecrease the
und to be a
 inflammat
 
ory 
Table 1. Intracellular sulfane sulfur stores. 
Sulfane Sulfur Stores 
Thiosulfate S2O3
2-
Persulfides R-S-SH
Thiosulfonates R-S(O)–S-R’
Polysulfides R-Sn-R
Polythionates SnO6 
2-
Elemental sulfur S
0 
Protein-associated 
sulfur 
On Rhodanese, CSE, MPST, 
etc  
Table 2. The benefits and disadvantages of the most commonly studied H2S donors 
H2S Donors H2S 
release 
mechanis
m  
Benefits  Disadvantages  Specie
s  
Ischemia 
Model  
H2S Gas  Authentic 
H2S 
resource  
• Authentic source
of H2S 
• Found to induce
suspended 
animation-like 
state in mice and 
reduce metabolic 
rate 
• Difficult to obtain
precisely controlled 
cellular concentrations 
of H2S over a 
prolonged period 
• Possible toxic impact
of H2S excess 
• Hibernation studies
have not been 
replicated in large 
animal models 
Mouse  Endotoxemia(99)
Metabolism(100)
Rat  Cerebral (101, 
102) 
Retinal (103) 
Metabolism(100, 
104) 
Rabbi
t 
Cerebral(105) 
Pig Metabolism(89) 
Sheep Metabolism(25) 
Inorganic 
Sulfide 
Salts 
(NaHS, 
Na2S)  
Hydrolysis  • Rapid boost of 
H2S 
concentration 
• Uncontrollable release
as soon as solution is
prepared
• Can be quickly lost
due to volatilization,
t1/2 ~5min
• Significant amount of
impurities, polysulfide
contamination
Mous
e 
Cardiac(106) 
GI(107) 
Hepatic(108) 
Renal(69) 
Rat Cerebral(109-
111) 
Cardiac (63, 64, 
112, 113) 
Hepatic(114, 
115) 
Renal(116-118) 
Cerebral(109-
111) 
Rabbi
t 
Cardiac(119) 
Pig Cardiac(120) 
Renal(71) 
Metabolism(30) 
Garlic-
Derived 
Organic 
Sulfur 
Compounds 
(diallyl 
thiosulfinat
e → diallyl 
sulfide 
(DAS), 
diallyl 
disulfide 
(DADS), 
Thiol 
Activation  
• H2S release
greatest from 
DATS 
>DADS>DAS
• Natural source of
H2S  
• Diallyl thiosulfinate is
unstable in aqueous 
solution and quickly 
decomposes to DAS, 
DADS, DATS and 
ajoene 
• DAS, DADS, and
DATS only produce 
H2S when they react 
with GSH and NADPH 
is necessary to support 
the activity of GSH 
reductase  
Mous
e 
Cerebral(121) 
Cardiac(122) 
Rat Cerebral (123-
125) 
Cardiac(126) 
Hepatic(127) 
Renal (128-130) 
Rabbi
t 
Cerebral (132) 
Cardiac(131) 
diallyl 
trisulfide 
(DATS), 
and ajoene)  
• Rate of release of H2S
from garlic-derived 
compounds still 
unknown 
• Unknown mechanism
of action of H2S 
release, effects may be 
derived from 
polysulfides  
1,2-
Dithiole-3-
Thinones 
(H2S hybrid 
drugs w/ 
NSAIDS)  
Hydrolysis  • Improvements in
side-effects of 
NSAIDs with 
hybridization 
with H2S 
• Significant
improvements in
activity profile of
NSAIDS as
hybrids
compared to
NSAIDS alone
• Known to also
significantly elevate in
vivo GSH level, may
contribute to
pharmacological
benefits
• Known to also
participate in other
biological reactions
including electrophilic
reactions and
conversion of
molecular oxygen to
ROS
Mous
e 
Cerebral(4, 133) 
Rat Cardiac (134, 
135) 
Rabbi
t 
Cardiac(136) 
GYY4137  Hydrolysis  • Slow-releasing
H2S donor 
• H2S
concentration 
reaches 
maximum value 
within 6-10 
minutes but at a 
very low level 
• pH and
temperature 
dependent with 
more release at 
acidic pH and 
less release at 
low temperatures 
• Fixed slow release may
not be of benefit in all 
disease models of 
ischemia 
• Byproducts produced
through H2S release 
still unknown  
Mous
e 
Cardiac(137) 
Rat Cardiac (138) 
GI (139) 
